EP
CORT icon

Essential Partners’s Corcept Therapeutics CORT Stock Holding History

Essential Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
+1,384
New +$83.6K 0.06% 363
2026
Q1 		– Sell
-301
Closed -$10.5K – 2877
2025
Q4 		$10.5K Sell
301
-290
-49% -$22.8K ﹤0.01% 1157
2025
Q3 		$49.1K Buy
591
+272
+85% +$19.7K 0.02% 599
2025
Q2 		$23.4K Buy
+319
New +$23.1K 0.01% 629

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's CORT Position: Q2 2026 in Review

Essential Partners opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 1,384 shares worth $120K. The stake represents 0.06% of the portfolio and ranks #363 among its holdings. This is a return to the name: Essential Partners previously reported a position in CORT as recently as Q4 2025.

Essential Partners first reported a position in CORT in Q2 2025 and has held it in 4 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Essential Partners held 1,384 shares of Corcept Therapeutics worth $120K as of Q2 2026.
  • Corcept Therapeutics was a new Essential Partners position in Q2 2026.
  • Corcept Therapeutics made up 0.06% of Essential Partners's portfolio in Q2 2026, its #363 holding.
  • Essential Partners first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.